Leerink Partners downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Underperform with a price target of $5.00 (from $13.00).Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE